Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial

The Lancet 2026 Open access

Read full text
Authors: Michel Azizi, Jenifer M. Brown, Jamie P. Dwyer, John M Flack, Erica S W Jones, Raisa Kurlyandskaya, Hongjian Li, Filip Birve, Aina S. Lihn, Shira Perl, Markus P. SCHLAICH, Hirotaka Shibata
+88 more Ji-Guang Wang, Bryan Williams, Cesar Zaidman, Sonia Sassone, Miguel Cuenca, Diego Arakaki, Mariano I. Chahin, María Andrea Steinacher, Fredy Ferre Pacora, Juan Loureyro, Jun Yang, Markus P. SCHLAICH, Tine De Backer, Hans T Kindt, P. Delmotte, Blagovest Stoimenov, Kiril Dzhomanov, Krassimir Cvetkov, Dimitar Raev, Stefan Naydenov, Shivinder Jolly, John Vyselaar, Luis Noronha, Daniel Gaudet, A. Shekhar Pandey, Jennifer Ringrose, Yves Robitaille, Jiri Vesely, Jiri Krupicka, Ladislav Busak, Jitka Pruchova, Wolfgang Jungmair, Sebastian Cremer, Markus van der Giet, Stephan H. Schirmer, Spasija Parizova, Michael Doumas, George Stergiou, Konstantinos Tsioufis, Zoltán Miklós Járai, András Vorobcsuk, Tibor Kiss, Gizella Pap, Andras Csaba Nagy, Attila Farkas, Desmond Samuel, Mohd Faiz Faizul Fauzi, Mohamad Muslim Jamian, Louie Tirador, Gabriel Jocson, Marek Rajzer, Andrzej Januszewicz, Andrzej Tykarski, Michał Hoffmann, Jan Zbigniew Peruga, Edyta Zbroch, Piotr Sobieraj, Abdulmajid Mukhtar, Talal Aljabbary, Lubomir Antalik, Ján Fedačko, Peter Fulop, Lesley Burgess, Gulam Latiff, Julián Segura de la Morena, José Antonio García Donaire, Miguel Camafort Babkowski, Alejandro de la Sierra, Javier Sobrino Martínez, Anna Oliveras Serrano, Fernando Martinez, Manuel Gorostidi Pérez, Francisco Fuentes Jimenez, Chern‐En Chiang, Kang-Ling Wang, Yen-Wen Wu, I-Chang Hsieh, Praew Kotruchin, Yongkasem Vorasettakarnkij, Weranuj Roubsanthisuk, Prin Vathesatogkit, Krit Leemasawat, Hilmi Erdem Sumbul, Özge Turgay Yıldırım, ÇAĞRI YAYLA, Ozkan Gungor, İsmail Koçyiğit, Auditi Naziat
DOI: 10.1016/s0140-6736(25)02549-8
Cited by: 24
References: 29

Abstract

BACKGROUND: Aldosterone dysregulation is an important contributor in the pathogenesis of hard-to-control hypertension. We aimed to assess the effect of baxdrostat, a selective aldosterone synthase inhibitor, on ambulatory blood pressure in patients with resistant hypertension. METHODS: The Bax24 international, phase 3, randomised, double-blind, placebo-controlled trial recruited adults (aged ≥18 years) with seated systolic blood pressure (SBP) ≥140 mm Hg and

Fields of Study & Subjects

Blood Pressure and Hypertension Studies Renin-Angiotensin System Studies Neurological Disorders and Treatments

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
407
Issue
10532
Pages
988–999
Publication date
1 March 2026
Language
EN